We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

75 hedge funds and large institutions have $494M invested in Epizyme, Inc in 2014 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 6

100% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 16

51% more capital invested

Capital invested by funds: $326M → $494M (+$168M)

25% more funds holding

Funds holding: 6075 (+15)

7% more call options, than puts

Call options by funds: $876K | Put options by funds: $815K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
75
Holders Change
+15
Holders Change %
+25%
% of All Funds
2.17%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
21
Increased
32
Reduced
16
Closed
6
Calls
$876K
Puts
$815K
Net Calls
+$61K
Net Calls Change
+$61K
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
$355K -$36.8K -1,214 -7%
TC
52
TFS Capital
Pennsylvania
$323K +$430K +14,195 New
SG Americas Securities
53
SG Americas Securities
New York
$317K +$422K +13,924 New
Group One Trading
54
Group One Trading
Illinois
$304K +$405K +13,364 New
AllianceBernstein
55
AllianceBernstein
Tennessee
$279K
DCM
56
Dupont Capital Management
Delaware
$279K
California State Teachers Retirement System (CalSTRS)
57
California State Teachers Retirement System (CalSTRS)
California
$278K +$45.5K +1,500 +14%
Millennium Management
58
Millennium Management
New York
$256K +$341K +11,261 New
Royal London Asset Management
59
Royal London Asset Management
United Kingdom
$248K +$333K +11,000 New
Swiss National Bank
60
Swiss National Bank
Switzerland
$173K +$127K +4,200 +124%
Barclays
61
Barclays
United Kingdom
$128K +$171K +5,653 +4,009%
NFA
62
Nationwide Fund Advisors
Ohio
$118K +$16.9K +556 +12%
AIG
63
American International Group
New York
$91.6K +$2.94K +97 +2%
U
64
UBS
Switzerland
$70K -$9.21K -304 -9%
CPA
65
Cowen Prime Advisors
New York
$67K +$89.4K +2,950 New
PCM
66
Prelude Capital Management
New York
$66K +$87.9K +2,900 New
TRCT
67
Tower Research Capital (TRC)
New York
$41K +$23K +758 +73%
SFU
68
Stonehage Fleming (UK)
United Kingdom
$34K
Teacher Retirement System of Texas
69
Teacher Retirement System of Texas
Texas
$9K +$4.94K +163 +77%
ClearBridge Investments
70
ClearBridge Investments
New York
$5K +$1.76K +58 +36%
BlackRock
71
BlackRock
New York
$4K +$1.91K +63 +48%
BNP Paribas Financial Markets
72
BNP Paribas Financial Markets
France
$1.29K +$818 +27 +84%
Manulife (Manufacturers Life Insurance)
73
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$112 -$4.94K -163 -3%
BC
74
Broadfin Capital
New York
-$2.08M -100,000 Closed
RFC
75
Russell Frank Company
Washington
-$2.77M -91,356 Closed

EPZM Hedge Fund Activity: Q1 2014 in Review

75 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2014, worth a combined $494M — up 51% from $326M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new EPZM positions and 6 closed out — a net gain of 15 holders — while 32 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was MPM Asset Management, cutting an estimated $14.1M.

  • 75 institutional investors held Epizyme, Inc (EPZM) as of Q1 2014, up from 60 in Q4 2013.
  • Funds reported $494M of Epizyme, Inc stock for Q1 2014, up 51% quarter-over-quarter.
  • 21 funds opened new Epizyme, Inc positions in Q1 2014 and 6 closed out, a net change of +15 holders.
  • The largest Epizyme, Inc buyer in Q1 2014 was Fidelity Investments, an estimated $53.1M added.
  • The largest Epizyme, Inc seller in Q1 2014 was MPM Asset Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q1 2014.